Neostem (NBS) 5.10 $NBS
NeoStem Announces Licensing Agreement and Plans to Begin Phase 2 Hepatocellular Carcinoma Trial in China
GlobeNewswire - 2 hrs 43 mins ago
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that the Company has signed an exclusive license agreement with China-based Cellular Biomedicine Group (OTCQB:CBMG) ("CBMG" to begin a Phase 2 clinical trial in patients with late stage liver cancer. The trial, to be conducted in China in accordance with international standards, will investigate the use of the Company's developmental patient-specific cancer immunotherapy known as "DC-TC", in patients with hepatocellular carcinoma ("HCC" .
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Stock to Watch: Neostem Up 7.2% (NBS)
Comtex SmarTrend(R) - Fri May 09, 10:40AM CDT
Neostem (AMEX:NBS) is one of today's best performing low-priced stocks, up 7.2% to $4.92 on 1.0x average daily volume. Thus far today, Neostem has traded 281,000 shares, vs. average volume of 281,000 shares per day. The stock has outperformed the Dow (7.2% to the Dow's -0.1%) and outperformed the S&P 500 (7.2% to the S&P's -0.3%) during today's trading.
NeoStem Announces Closing of Acquisition of California Stem Cell, Inc. and First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, today announced first quarter 2014 financial results as well as the closing of the Company's acquisition of California Stem Cell, Inc. ("CSC" , an Irvine, California based biotechnology company. Strategic acquisitions that leverage the Company's strong development, regulatory and manufacturing expertise have been the cornerstone of NeoStem's growth and the basis for providing value to shareholders.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
NeoStem, Inc. - "Are All Cardiovascular Cell Therapies Created Equal?"
ACCESSWIRE - Mon May 05, 9:03AM CDT
Pittsburgh, PA / May 5, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer Dr. Douglas W. Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple May Conferences
GlobeNewswire - Mon May 05, 8:42AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in May.
NeoStem, Inc. - "Manufacturing Considerations for NeoStem's Acquisition of California Stem Cell"
ACCESSWIRE - Thu May 01, 10:46AM CDT
Pittsburgh, PA / May 1, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Scientific Officer Dr. Robert A. Preti. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem's Subsidiary, Progenitor Cell Therapy Enters Into a Services Agreement With IRX Therapeutics, Inc.
GlobeNewswire - Wed Apr 30, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , announced the execution of a Services Agreement with IRX Therapeutics, Inc. ("IRX" under which PCT will provide services to support IRX's development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to activate a patient's immune system to broadly restore immunity and overcome cancer-induced immune suppression. IRX has engaged PCT for the manufacture of an intermediate component referred to as IRX-2 Drug Substance for human clinical trials.
NeoStem, Inc. - "Welcome to Dr. Losordo's Blog"
ACCESSWIRE - Thu Apr 24, 10:26AM CDT
Pittsburgh, PA / April 24, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer Dr. Doug Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
CEO Dr. Robin Smith of NeoStem to Discuss Agreement to Acquire California Stem Cell, Inc. Live Today on Clear Channel's "The Traders Network Show"
Marketwire - Tue Apr 15, 6:16AM CDT
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem" , a leader in the emerging cellular therapy industry, announced today that Chairman and CEO, Dr. Robin Smith, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. In this exclusive 2-segement interview, Dr. Smith will go over the strategic details of their contract to acquire California Stem Cell, Inc. (CSC) .
Why NeoStem (NBS) Stock Is Up Today
at The Street - Mon Apr 14, 2:57PM CDT
NeoStem (NBS) shares are up 5.8% to $6.77 in trading on Monday
NeoStem Inc. "Continued Growth through Strategic Acquisitions"
ACCESSWIRE - Mon Apr 14, 9:16AM CDT
PITTSBURGH, PA / April 14, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc.
GlobeNewswire - Mon Apr 14, 6:11AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC" , an Irvine, California based stem cell biotechnology company. As a result of this acquisition, NeoStem plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence.
NeoStem Announces Conference Call and Webcast
GlobeNewswire - Fri Apr 11, 3:14PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that it plans to conduct a conference call and webcast. The call and webcast will be on Monday, April 14, at 10:00 AM EDT. To access the webcast, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events or call 1-855-235-8282 and provide Conference ID 29328201.
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
NeoStem, Inc. "An Update from Dr. Robin Smith, Chairman and CEO"
ACCESSWIRE - Mon Apr 07, 9:17AM CDT
PITTSBURGH, PA/ ACCESSWIRE / April 7th, 2014 NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
BTV-Business Television - Neostem Developing Cell Based Therapeutics to Prevent, Treat or Cure Disease
Newsfile Corp - Fri Apr 04, 1:00PM CDT
full story)
NeoStem Announces Licensing Agreement and Plans to Begin Phase 2 Hepatocellular Carcinoma Trial in China
GlobeNewswire - 2 hrs 43 mins ago
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that the Company has signed an exclusive license agreement with China-based Cellular Biomedicine Group (OTCQB:CBMG) ("CBMG" to begin a Phase 2 clinical trial in patients with late stage liver cancer. The trial, to be conducted in China in accordance with international standards, will investigate the use of the Company's developmental patient-specific cancer immunotherapy known as "DC-TC", in patients with hepatocellular carcinoma ("HCC" . Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Stock to Watch: Neostem Up 7.2% (NBS)
Comtex SmarTrend(R) - Fri May 09, 10:40AM CDT
Neostem (AMEX:NBS) is one of today's best performing low-priced stocks, up 7.2% to $4.92 on 1.0x average daily volume. Thus far today, Neostem has traded 281,000 shares, vs. average volume of 281,000 shares per day. The stock has outperformed the Dow (7.2% to the Dow's -0.1%) and outperformed the S&P 500 (7.2% to the S&P's -0.3%) during today's trading.
NeoStem Announces Closing of Acquisition of California Stem Cell, Inc. and First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, today announced first quarter 2014 financial results as well as the closing of the Company's acquisition of California Stem Cell, Inc. ("CSC" , an Irvine, California based biotechnology company. Strategic acquisitions that leverage the Company's strong development, regulatory and manufacturing expertise have been the cornerstone of NeoStem's growth and the basis for providing value to shareholders. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
NeoStem, Inc. - "Are All Cardiovascular Cell Therapies Created Equal?"
ACCESSWIRE - Mon May 05, 9:03AM CDT
Pittsburgh, PA / May 5, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer Dr. Douglas W. Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple May Conferences
GlobeNewswire - Mon May 05, 8:42AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in May. NeoStem, Inc. - "Manufacturing Considerations for NeoStem's Acquisition of California Stem Cell"
ACCESSWIRE - Thu May 01, 10:46AM CDT
Pittsburgh, PA / May 1, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Scientific Officer Dr. Robert A. Preti. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem's Subsidiary, Progenitor Cell Therapy Enters Into a Services Agreement With IRX Therapeutics, Inc.
GlobeNewswire - Wed Apr 30, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"
, announced the execution of a Services Agreement with IRX Therapeutics, Inc. ("IRX" under which PCT will provide services to support IRX's development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to activate a patient's immune system to broadly restore immunity and overcome cancer-induced immune suppression. IRX has engaged PCT for the manufacture of an intermediate component referred to as IRX-2 Drug Substance for human clinical trials. NeoStem, Inc. - "Welcome to Dr. Losordo's Blog"
ACCESSWIRE - Thu Apr 24, 10:26AM CDT
Pittsburgh, PA / April 24, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer Dr. Doug Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
CEO Dr. Robin Smith of NeoStem to Discuss Agreement to Acquire California Stem Cell, Inc. Live Today on Clear Channel's "The Traders Network Show"
Marketwire - Tue Apr 15, 6:16AM CDT
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem"
, a leader in the emerging cellular therapy industry, announced today that Chairman and CEO, Dr. Robin Smith, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. In this exclusive 2-segement interview, Dr. Smith will go over the strategic details of their contract to acquire California Stem Cell, Inc. (CSC) . Why NeoStem (NBS) Stock Is Up Today
at The Street - Mon Apr 14, 2:57PM CDT
NeoStem (NBS) shares are up 5.8% to $6.77 in trading on Monday
NeoStem Inc. "Continued Growth through Strategic Acquisitions"
ACCESSWIRE - Mon Apr 14, 9:16AM CDT
PITTSBURGH, PA / April 14, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc.
GlobeNewswire - Mon Apr 14, 6:11AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC" , an Irvine, California based stem cell biotechnology company. As a result of this acquisition, NeoStem plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. NeoStem Announces Conference Call and Webcast
GlobeNewswire - Fri Apr 11, 3:14PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that it plans to conduct a conference call and webcast. The call and webcast will be on Monday, April 14, at 10:00 AM EDT. To access the webcast, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events or call 1-855-235-8282 and provide Conference ID 29328201. Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
NeoStem, Inc. "An Update from Dr. Robin Smith, Chairman and CEO"
ACCESSWIRE - Mon Apr 07, 9:17AM CDT
PITTSBURGH, PA/ ACCESSWIRE / April 7th, 2014 NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
BTV-Business Television - Neostem Developing Cell Based Therapeutics to Prevent, Treat or Cure Disease
Newsfile Corp - Fri Apr 04, 1:00PM CDT
full story)
